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Abstract
Sparstolonin B (SsnB) is a novel bioactive compound isolated from Sparganium stoloniferum, an herb historically used in
Traditional Chinese Medicine as an anti-tumor agent. Angiogenesis, the process of new capillary formation from existing
blood vessels, is dysregulated in many pathological disorders, including diabetic retinopathy, tumor growth, and
atherosclerosis. In functional assays, SsnB inhibited endothelial cell tube formation (Matrigel method) and cell migration
(Transwell method) in a dose-dependent manner. Microarray experiments with human umbilical vein endothelial cells
(HUVECs) and human coronary artery endothelial cells (HCAECs) demonstrated differential expression of several hundred
genes in response to SsnB exposure (916 and 356 genes, respectively, with fold change $2, p,0.05, unpaired t-test).
Microarray data from both cell types showed significant overlap, including genes associated with cell proliferation and cell
cycle. Flow cytometric cell cycle analysis of HUVECs treated with SsnB showed an increase of cells in the G1 phase and a
decrease of cells in the S phase. Cyclin E2 (CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins that control cell
cycle progression through the G1/S checkpoint. Both CCNE2 and CDC6 were downregulated in the microarray data. Real
Time quantitative PCR confirmed that gene expression of CCNE2 and CDC6 in HUVECs was downregulated after SsnB
exposure, to 64% and 35% of controls, respectively. The data suggest that SsnB may exert its anti-angiogenic properties in
part by downregulating CCNE2 and CDC6, halting progression through the G1/S checkpoint. In the chick chorioallantoic
membrane (CAM) assay, SsnB caused significant reduction in capillary length and branching number relative to the vehicle
control group. Overall, SsnB caused a significant reduction in angiogenesis (ANOVA, p,0.05), demonstrating its ex vivo
efficacy.
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Introduction
Sparstolonin B (SsnB) is a novel bioactive compound isolated
from the plant Sparganium stoloniferum, a perennial, aquatic plant
grown in North and East China, whose tubers have long been used
in Traditional Chinese Medicine (TCM) for the treatment of
several inflammatory diseases and as an anti-spasmodic and anti-
tumor agent. NMR and X-ray crystallography have identified
SsnB as a polyphenol with structural similarities to isocoumarins, a
class of compounds that often exhibit anti-coagulant, anti-
inflammatory, and anti-tumor properties [1–3]. SsnB may hold
potential as a safe, non-toxic pharmaceutical agent for the
treatment of several pathological conditions. At concentrations
up to 100 mM, SsnB does not exhibit cytotoxic effects on various
cell types, including mouse peritoneal macrophages, HUVECs,
human aortic smooth muscle cells, and monocytic THP-1 cells [3].
Prior research has shown that SsnB exhibits strong anti-
inflammatory effects on mouse and human macrophages by
selectively inhibiting the inflammatory responses of macrophages
to ligands for Toll-like Receptor (TLR) 2 and TLR4. SsnB has also
been shown to suppress downstream signaling pathways after
TLR2 and TLR4 activation, including MAPK and NF-kB [3].
These findings suggest that SsnB may be an antagonist to TLR2
and TLR4.
Angiogenesis refers to capillary formation from existing blood
vessels. Angiogenesis plays an important role in many physiolog-
ical events in the body, including wound healing, embryogenesis,
and female reproductive processes [4,5]. During these normal
processes, angiogenesis is highly regulated. Unregulated, excessive
angiogenesis contributes to many pathologies, such as rheumatoid
arthritis, psoriasis, retinopathy, and tumor growth and metastasis
[6]. Inhibiting pathological angiogenesis may prove to be an
effective therapy for these angiogenesis-related diseases.
Angiogenesis is a complex process that occurs in several stages
and involves interactions between cells, soluble factors, and
extracellular matrix molecules. Endothelial cells play a key role
in angiogenesis. Endothelial cells can secrete proteolytic enzymes
which break down the basement membrane of an existing blood
vessel, allowing the cells to invade the surrounding tissues, migrate
in response to an angiogenic stimulus, and proliferate. Growth
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factors and other soluble proteins in the ECM often facilitate and
regulate this process, including vascular endothelial growth factor
(VEGF). The endothelial cells form a new lumen, start to secrete
extracellular matrix molecules, and ultimately form a new
capillary [7–9]. Mural cells are also recruited to the site and play
an important role in angiogenesis. Angiogenesis may be inhibited
at any of these key steps [10]. Targeting endothelial cell
proliferation, cell migration, and chemotaxis have shown potential
in angiogenesis inhibition.
In the present study, we demonstrate that SsnB inhibits
endothelial cell functions related to angiogenesis in several in vitro
functional assays, and we also show that SsnB inhibits angiogenesis
in an ex vivo assay. The data suggests the potential of SsnB as an
anti-angiogenic agent by showing inhibition of human endothelial
cell tube formation and migration. We have also examined the
effects of SsnB on endothelial cell gene expression, focusing in
particular on pathways related to angiogenesis. In addition, our
data show that SsnB arrests endothelial cell division in the G1
phase and downregulates the cell cycle proteins cdc6 and cyclin
E2. Furthermore, SsnB caused a significant reduction in blood
vessel length and branching number in the chick chorioallantoic
membrane assay. Overall, these findings add anti-angiogenic and
cytostatic properties to the list of diverse effects exhibited by SsnB.
Experimental Procedures
Materials
Sparstolonin B was purified from the plant Sparganium stoloniferum
according to previously published methods [3]. The purity of SsnB
was determined to be greater than 99% by HPLC, and a stability
test was utilized to ensure that samples were consistently .99%
pure.
Cell Culture – Human coronary artery endothelial cells
(HCAECs), human umbilical vein endothelial cells (HUVECs),
and human cardiac microvascular endothelial cells (HMVECs)
were obtained from Lonza (Hopkinton, MA) and cultured on
polystyrene, tissue culture-treated petri plates (100620 mm)
coated with 0.1% gelatin. HUVECs, HCAECs, and HMVECs
were cultured in endothelial cell medium supplemented with 10%
fetal bovine serum (FBS) and endothelial cell mitogen/growth
supplement (Biomedical Technologies, Stoughton, MA). The
endothelial cell medium was replaced every 2–3 days, and the
cells were passaged after complete confluence was reached.
Confluent plates were trypsinized and split, and the cells were
cultured until the fourth passage was reached.
Matrigel Tube Formation Assay
To initially determine if SsnB inhibited pro-angiogenic cell
functions, a tube formation assay with Matrigel was performed.
Growth factor reduced Matrigel (BD Biosciences, Bedford, MA)
was added to the wells of a 96 well polystyrene culture plate and
incubated at 37uC for 30 minutes. Cells (HUVECs, HCAECs, or
HMVECs at passage 2 to 4) were added to each well to reach a
final number of 20,000 cells per well. SsnB was added to the wells
at a concentration of 1, 10, or 100 mM. Endothelial cell medium
with DMSO (0.1%) was used as a vehicle control. Each group
contained 4 replicates. The plates were placed in an incubator for
4 h. During the incubation, the endothelial cells formed elongated
structures called cords, also known as tubes. After 4 h, neutral
buffered formalin was added to fix the cells. Pictures of three non-
overlapping fields were taken from each well. The lengths of single
cell endothelial cords were measured with Image-Pro Plus (Media
Cybernetics, Silver Spring, MD), and the sum of tube lengths for
each well was determined. The average total length and standard
deviation for each group were determined, and the appropriate
statistical tests (ANOVA and Newman-Keuls) were completed.
The tube formation assay was replicated three times for both
HUVECs and HCAECs. The assay was also repeated with cardiac
HMVECs.
Cell Viability
A Live/Dead assay (Invitrogen, Eugene, OR) was utilized to
investigate the effect of SsnB on cell viability. The Matrigel tube
formation experiment was repeated with HUVECs in chamber
slides at a concentration of 20,000 cells per well. The cells were
treated with SsnB (1, 10, or 100 mM) or Vehicle Control (0.1%
DMSO) as described above. After four hours of incubation, the
slides were removed. A chamber slide containing HUVECs
treated with 70% methanol for 30 minutes was used as a control
for dead cell staining. The slides were aspirated and washed with
PBS, and EthD-1 and calcein AM were added to each well. The
plates were incubated in the dark, and images were taken with a
light microscope at 10X magnification.
Transwell Insert Cell Migration Assay
The cell invasion assay was performed with a Transwell insert
system (6.5 mm diameter inserts with 8.0 mm pores in a
polycarbonate membrane situated in wells of 24 well polystrene,
tissue culture-treated plates, Corning Incorporated, Corning, NY).
The Transwell inserts were coated with 0.1% gelatin for 30 min
and incubated in low serum medium for 1 h. Cultured HUVECs
were trypsinized and then resuspended in low serum medium
(0.5% fetal bovine serum without endothelial cell mitogen), and
added at 50,000 cells per insert. The cells were allowed to adhere
to the inserts for 30 min. Next, various concentrations of SsnB
(0.0001, 0.001, 0.01, 0.1, 1, 10, and 100 mM) or vehicle control
(0.1% DMSO) were added to the Transwell inserts. After 30 min,
the medium in the lower chamber for the experimental groups was
replaced with low serum medium containing 10 ng/ml VEGF,
establishing a chemoattractant gradient between the top insert and
lower chamber. For the negative control group, the medium was
replaced with low serum medium (0.5% fetal bovine serum). The
plates were incubated for 8 h at 37uC. During the incubation, the
cells migrated through the pores of the Transwell insert towards
the lower chamber. At the end of this period, cells on the upper
surface of the insert were removed, and migrated cells on the
bottom side were fixed in formalin and stained with Hoechst dye (a
fluorescent nuclear stain). The filter inserts were removed from the
wells and mounted on glass slides. Cells were counted from four
random fields observed with a 10X objective lens. The cell
migration experiments were repeated three times at high SsnB
concentrations (0.1, 1, 10, 100 mM) and one time at low SsnB
concentrations (0.0001, 0.001, 0.01, 0.1 mM) for HUVECs.
Cell Cycle Analysis
Cell cycle analysis was performed using propidium iodide
staining and flow cytometry. HUVECs (approximately 75%
confluent) cultured in 6 well polystyrene culture plates coated
with 0.1% gelatin were serum starved for 24 hours in low serum
medium containing 0.5% fetal bovine serum and no endothelial
cell mitogen to synchronize the cells in the G0/G1 phase. After
24 hours, the low serum medium was replaced with treatments of
either 100 mM SsnB or vehicle control (0.1% DMSO) diluted in
complete growth medium (10% fetal bovine serum with endothe-
lial cell mitogen) in triplicate. The treated cells were incubated for
24, 30, and 36 hours. After incubation, the cells were trypsinized,
transferred to 5 ml polysytrene round bottom tubes (12675 mm),
and centrifuged. The medium was aspirated, and the cells were
Sparstolonin B Inhibits Pro-Angiogenic Functions
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washed with PBS. After fixing the cells with ice-cold 70% ethanol
for 15 min, the cells were centrifuged and stained with propidium
iodide for 30 min. The samples were then analyzed with a flow
cytometer (Beckman Coulter FC500). The unstained and stained
cell groups were used to calibrate the settings on the flow
cytometer. The data were collected and analyzed with ModFit
software.
Microarray Analysis
Confluent plates (100620 mm polystyrene, tissue culture-
treated petri plates coated with 0.1% gelatin, 75% confluent) of
HUVECs and HCAECs (four plates for HUVECs, n = 2, and six
plates for HCAECs, n = 3) were chosen for the microarray
experiments. Half of the plates received complete growth medium
(10% fetal bovine serum with endothelial mitogen) containing
vehicle control (0.1% DMSO), and the remaining plates received
complete growth medium containing 100 mM SsnB. The plates
were incubated for 24 h to allow SsnB to have an effect on cellular
gene expression. Following incubation, RNA isolation was
completed with the RNeasy Mini kit from Qiagen. The cells were
lysed, and RNA was isolated by using the RNeasy spin columns
and following the protocol provided by Qiagen. Purified RNA was
sent to the Medical University of South Carolina Proteogenomics
Facility for microarray analysis. The GeneChip Human Genome
U133 Plus 2.0 Array was utilized to track changes in gene
expression due to SsnB treatment. Complete data was uploaded to
the NCBI Gene Expression Omnibus database (accession number
GSE44598).
Real Time RT-PCR
After a careful analysis of the microarray data, key genes
(CDC6, CCNE2, KITLG, ALDH3A1, CCNB1, CDC2, HMMR,
DIAPH3, ANLN, and CDKN3) were chosen for quantitative real-
time PCR (qRT-PCR) to verify the gene expression results.
HCAECs and HUVECs were exposed to SsnB or vehicle control
for 24 h (as previously described in the microarray section). For
RT-PCR, RNA was isolated from the cells with the RNeasy Mini
kit as described previously. After forward and reverse primer kits
(Qiagen, Valencia, CA) were selected, the RNA was amplified.
The one-step RT-PCR reactions were completed on the BioRad
iCycler thermal cycler system in the Instrumentation Resource
Facility at the USC School of Medicine. The expression levels
were normalized, and RNA levels were quantified.
Data Analysis
Microarray data analysis, including data normalization (robust
multi-array average), identification of differentially expressed
genes (comparative analyses with dChip software), and heat map
construction, was carried out to determine how SsnB affects gene
expression and affected pathways (n = 2 for HUVECs and n= 3
for HCAECs). After a careful analysis of the microarray data,
several key genes were chosen for qRT-PCR to verify the gene
expression results. The genes were chosen based on the following
criteria: fold change $2, p,0.05, unpaired t-test with a false
discovery rate approximating 0%, appearing in both data sets
(HUVECs and HCAECs), and gene function relating to cell
proliferation and/or angiogenesis. For qRT-PCR, the expression
levels were normalized to the housekeeping gene GAPDH, and
RNA levels were compared between groups with the DDCt
method.
Chick Chorioallantoic Membrane (CAM) Assay
Fresh fertilized Bovans eggs were obtained from Clemson
University and stored at 4uC for no longer than one week.
Methylcellulose discs were created with a solution of 0.5%
methylcellulose (diluted in sterile deionized water). A methylcel-
lulose solution of 100 micromolar SsnB was made by adding
1.1 microliters of stock SsnB (93 mM) to 1 ml 0.5% methylcellu-
lose. A vehicle control solution was created by adding 1 microliter
of dimethyl sulfoxide (DMSO) to 1 ml 0.5% methylcellulose. Discs
were created by placing 20 microliter droplets of SsnB or vehicle
control solution onto polytetrafluoroethylene tape (to minimize
adherence during drying) and allowed to dry under a laminar flow
hood. The fertilized eggs were placed in a humidified egg
incubator with forced air circulation at 37uC. The eggs were
automatically rotated every three hours. After 4 days of incuba-
tion, the eggs were removed and cracked. Chick embryos with
intact yolks were placed in 100 mm petri plates. Each petri plate
was placed in a weigh boat containing 13 ml Moscona’s buffer and
covered with cellophane wrap with two holes for air circulation.
The plates were placed in a water-jacketed incubator (37C, 5%
CO2) for 2 days. After 2 days of incubation, the methylcellulose
discs containing either SsnB or vehicle control were placed on top
of the CAM of each embryo in the right upper quadrant in an area
near the allantoic vessels. After 2 additional days of incubation, the
CAMs were examined and photographed with a dissecting
stereomicroscope. Images of areas containing the discs and non-
treated regions were analyzed with Image-Pro Plus software.
Blood vessel length and branching number were quantified to
measure the effect of SsnB on angiogenesis. The total vessel length
was measured for areas containing the discs and for non-treated
areas of the same size. Normalized vessel length was calculated by
dividing the total length values of the treated regions by those of
the non-treated regions. The same process was repeated for
measuring the branching number. Each group contained seven
embryos (calculated with PS 3.0.5 software, effect size of 50%,
standard deviation of 30%, statistical power of 0.8, and a=0.05).
The CAM assay was completed two times.
Results
SsnB inhibits endothelial cell tube formation and cell
migration
Figures 1 and 2 show representative results from the tube
formation and cell migration assays with HUVECs. SsnB
treatment resulted in a dose-dependent inhibition of HUVEC
tube formation at concentrations between 1 and 100 mM (p,0.05,
Newman-Keuls test). SsnB also demonstrated a dose-dependent
inhibition of VEGF-induced cell migration at concentrations
between 0.0001 and 0.1 mM (p,0.05), which leveled off between
0.1 and 100 mM (p,0.05). Experiments with HCAECs also
demonstrated a dose-dependent inhibition (between 1 and
100 mM) of endothelial cell tube formation on the substrate
Matrigel (Figure 1B). A dose-dependent inhibition of tube
formation was also seen with cardiac HMVECs (see Figure S1).
Results from the live/dead assay with HUVECs showed that SsnB
had no effect on cell viability at the concentrations used. Cells
treated with SsnB or vehicle control showed positive staining for
live cells, but no staining for dead cells (red fluorescence). These
data suggest that SsnB is able to inhibit endothelial cell
morphogenesis and that cell migration, a crucial process in
angiogenesis, may play a role.
Sparstolonin B Inhibits Pro-Angiogenic Functions
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SsnB arrests endothelial cells in the G1 phase of the cell
cycle
Figure 3 depicts representative results from the cell cycle
experiments. In comparison to vehicle controls, flow cytometric
cell cycle analysis of HUVECs treated with SsnB showed an
increase of cells in the G1 phase and a decrease of cells in the S
phase after 24, 30, and 36 hours of treatment. In untreated cells,
the percentage of cells in S phase decreased and the percentage in
G2/M increased from 24 to 36 hours after addition of growth
medium, as expected once cells begin to re-enter and move
through the cell cycle. Overall, these results imply that endothelial
cells are being arrested in the G0/G1 phase, suggesting an
inhibition of cell proliferation, an important step in angiogenesis.
SsnB changes the expression of genes associated with
cell cycle and cell proliferation
Microarray experiments demonstrated differential expression of
several hundred genes in response to SsnB exposure (916 genes for
HUVECs and 356 genes for HCAECs, fold change $2, p,0.05,
unpaired t-test with a false discovery rate approximating 0%).
Table S1 and Table S2 present the results of the gene function
enrichment analysis for HUVECs and HCAECs, respectively.
Overall, microarray data from both cell types showed significant
overlap, including genes in pathways associated with cell
proliferation, cytoskeleton, chemotaxis, and cell cycle, all areas
implicated in angiogenesis. These results are consistent with the
data obtained from the cell migration and cell cycle functional
studies. From this microarray study, it is clear that SsnB regulates
genes involved in angiogenic processes in HUVECs and
HCAECs.
Real Time RT-PCR
Following microarray data analysis, key genes (listed in Table 1)
were chosen for verification with real time RT-PCR. Cyclin E2
(CCNE2) and Cell division cycle 6 (CDC6) are regulatory proteins
that control cell cycle progression through the G1/S checkpoint.
Both CCNE2 and CDC6 were downregulated in the microarray
data. qRT- PCR confirmed that gene expression of CCNE2 and
CDC6 was downregulated after SsnB exposure to 64% and 35%
of controls, respectively, for HUVECs and to 57% and 14% of
controls, respectively, for HCAECs. Kit-Ligand (KITLG), also
Figure 1. SsnB inhibits endothelial cell tube formation on Matrigel. A. Total tube length as a function of SsnB concentration in HUVECs. B.
Total tube length as a function of SsnB concentration in HCAECs. *p,0.05 vs. vehicle control, Newman-Keuls test. C. Representative micrographs
demonstrating tube formation in HUVECs (left – vehicle control, right – 100 mM SsnB).
doi:10.1371/journal.pone.0070500.g001
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known as stem cell factor, is a protein involved in the
differentiation and growth of stem cells. Aldehyde dehydrogenase
3 family, member A1 (ALDH3A1) is a protein involved in the aryl
hydrocarbon receptor pathway. These genes were chosen for
further study because they were highly upregulated by SsnB
treatment in the microarray data set. In HUVECs, qRT-PCR
analysis demonstrated that KITLG and ALDH3A1 expression
was upregulated to 400% and 1280% of controls, respectively. In
HCAECs, KITLG and ALDH3A1 expression was upregulated to
260% and 4620% of controls, respectively. The microarray data
was supported in both data sets.
SsnB inhibits ex vivo angiogenesis in the CAM assay
The results from the CAM assay are depicted in Figure 4.
Overall, SsnB treatment resulted in a significant decrease in
normalized blood vessel length compared to the vehicle control
group (ANOVA, p,0.05). In addition to reducing total blood
vessel length, SsnB treatment also resulted in a significant decrease
in the normalized branch number. Compared to the vehicle
control, SsnB decreased the number of points where blood vessels
branched into two or more separate vessels. Representative images
of the CAM from the SsnB and vehicle control groups after two
days of treatment are shown in figure 4. The methylcellulose discs
released SsnB or vehicle control and were still present at the end of
the experiment, as complete biodegradation did not occur. The
transparency of the methylcellulose discs allowed easy imaging of
the vascular network underneath the discs. Images were taken of
regions of the CAM that received methylcellulose discs as well as
regions that did not receive discs. For each embryo, the blood
vessel length and branch number were measured for both treated
and non-treated areas. A normalized value was calculated by
Figure 2. SsnB inhibits endothelial cell migration. A. Migrated cells as a function of SsnB concentration (0.1 to 100 mM). B. Migrated cells as a
function of SsnB concentration (0.0001 to 0.1 mM) shows a dose-dependent response. *p,0.05 vs. vehicle control, Newman-Keuls test. C.
Representative micrographs demonstrating cell migration (left – vehicle control, center – negative control, right – 100 mM SsnB).
doi:10.1371/journal.pone.0070500.g002
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dividing the treated areas by the non-treated areas. This approach
allowed us to compensate for natural variations in vascular density
among embryos that normally occur even in the absence of
angiogenic inhibitors or stimulators. Overall, the SsnB-treated
group showed fewer blood vessels, reduced vessel lengths, and
fewer branches. The methylcellulose discs with SsnB not only
inhibited angiogenesis in the area underneath the disc, but also
demonstrated inhibition in the immediate area surrounding the
discs. Compared to the SsnB group, the vehicle control group
exhibited greater vessel lengths, more numerous vessels, and more
Figure 3. SsnB arrests endothelial cells in the G1 phase of the cell cycle. A. After 24, 30, and 36 hours of treatment, 100 mM SsnB decreased
the percentage of cells in the S phase and increased the percentage of cells in the G1 phase. *p,0.005 vs. corresponding vehicle control, Newman-
Keuls test. B. Representative cell cycle data demonstrating the increase in G1 cell percentage and decrease in S phase cell percentage after 24 hours
of SsnB treatment (left – vehicle control, right – SsnB).
doi:10.1371/journal.pone.0070500.g003
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vascular branching. In addition, SsnB had no effect on the viability
or morphology of the embryos relative to the vehicle control.
Discussion
Pathological angiogenesis is associated with many disorders,
including rheumatoid arthritis, diabetic retinopathy, and psoriasis.
Recent research has shown that inhibiting angiogenesis may prove
to be an effective therapeutic option in treating these disorders. In
the present study, potential anti-angiogenic effects of SsnB were
demonstrated in the ex vivo CAM assay and in several in vitro
functional assays with endothelial cells, including the Matrigel tube
formation assay and the Transwell insert cell migration assay.
SsnB was also shown to arrest endothelial cells in the G1 phase of
the cell cycle. The cellular functions tested in these assays
represent key steps in angiogenesis that are inhibited by SsnB,
including cell proliferation, cell migration, and chemotaxis. To
further investigate the mechanism of action for SsnB, we utilized
microarray analysis to examine how SsnB affected gene expression
in endothelial cells. After SsnB exposure, genes associated with cell
proliferation, cell cycle, chemotaxis, and the cytoskeleton were
differentially regulated in both HUVECs and HCAECs. Our data
suggest that SsnB alters gene expression in these pro-angiogenic
pathways.
Targeting endothelial cell proliferation has shown potential in
the area of angiogenesis inhibition. Endothelial cell proliferation
may be inhibited in numerous ways, including the downregulation
of cell cycle regulatory proteins [10]. Cyclins and cyclin dependent
kinases are regulatory proteins that control progression through
the cell cycle by regulating specific cell cycle checkpoints. Cyclins
help activate cyclin dependent kinases, which phosphorylate
downstream proteins that allow cells to progress through these
checkpoints. Cyclin E2 (CCNE2) and Cell division cycle 6 (CDC6)
are regulatory proteins that control progression through the G1/S
checkpoint. CDC6 regulates DNA replication, and cyclin E2
activates cyclin-dependent kinase 2 [11,12]. Downregulation of
CCNE2 and CDC6 will trap cells at the G1/S checkpoint and
prevent endothelial cells from initiating DNA replication. Genes
encoding the cell cycle regulatory proteins, Cyclin E2 (CCNE2)
and Cell division cycle 6 (CDC6), were both downregulated by
SsnB treatment. Overall, our data suggest that SsnB downregu-
lates the cell cycle regulatory proteins CCNE2 and CDC6,
potentially trapping cells in the G1 phase and hindering cell
proliferation, an important step in angiogenesis [13–16].
Our data show that SsnB affects the gene expression of
additional cell cycle regulatory proteins, including cyclin B1
(CCNB1) and cyclin dependent kinase 1 (CDC2). CCNB1 and
CDC2 are regulatory proteins that control progression through
the G2/M checkpoint. Downregulation of CCNB1 and CDC2
will trap cells at the G2/M checkpoint and prevent endothelial
cells from entering the final stages of cell division. Table 1
demonstrates that CCNB1 and CDC2 were both downregulated
by SsnB. In addition to preventing cell progression through the G1
checkpoint, SsnB may also prevent progression through the G2/M
checkpoint by downregulating these additional cell cycle proteins
[13–16]. This effect is less readily seen due to blockage at the G1
checkpoint in synchronized cells.
Sparganium stoloniferum has long been used in Traditional Chinese
Medicine for the treatment of cancer and seizures. Major chemical
components from the stem and rhizome, including flavonoids,
saponins, and phenylpropanoids, are responsible for these
therapeutic effects [17]. Anti-tumor agents often exhibit anti-
angiogenic effects, among other cancer suppressing properties.
Inhibiting angiogenesis cuts tumors off from the vasculature,
limiting growth and metastasis [18]. Previously published research
has shown that extracts derived from Sparganium stoloniferum have
demonstrated potent anti-cancer effects. Isolated chemical com-
pounds from this herb, including a sucrose ester, a phenylpropa-
noid glycerol, carboxylic acid esters, and a phenylpropanoid
glycoside, demonstrated anti-tumor activities [2,19]. In addition,
the polyphenolic structure of SsnB also reveals much about its
potential therapeutic effects. Many plant-derived polyphenols have
demonstrated anti-inflammatory and anti-angiogenic properties.
Quercetin and resveratrol, both polyphenols isolated from red
wine, have demonstrated anti-inflammatory and anti-angiogenic
properties. In addition, oleuropein and hydroxytyrosol, both
derived from virgin olive oil, reduce angiogenesis by inhibiting
matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2
(COX-2) [20]. Emodin, another plant-derived polyphenol similar
to SsnB, has also been shown to inhibit angiogenesis by targeting
endothelial cell proliferation [21]. Emodin causes a downregula-
tion of CCNB1 and CDC2 and a cell cycle arrest at the G2/M
phase [22].
Table 1. Comparison of RT-PCR and Microarray Results.
HUVECs HCAECs
Gene 2DDCt Value Microarray Value
Microarray
p-value 2DDCt Value Microarray Value
Microarray
p-value
KITLG 4.0 6.2 0.02795 2.6 2.1 0.00010
ALDH3A1 12.8 7.7 0.00609 46.2 8.8 0.00001
HMMR 0.24 0.11 0.03073 0.062 0.20 0.00006
DIAPH3 0.19 0.34 0.03248 0.26 0.38 0.00019
ANLN 0.20 0.09 0.00900 0.13 0.11 0.000001
CDKN3 0.18 0.19 0.01471 0.22 0.18 0.00018
CCNB1 0.40 0.19 0.02304 0.13 0.16 0.00003
CDC2 0.14 0.08 0.00440 0.17 0.20 0.00004
CDC6 0.35 0.23 0.01527 0.14 0.18 0.00185
CCNE2 0.64 0.24 0.01814 0.57 0.38 0.00180
Fold expression change vs. vehicle control.
doi:10.1371/journal.pone.0070500.t001
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In addition to its effects on the cell cycle and cell proliferation,
SsnB also affects other key steps of angiogenesis, including cell
migration and chemotaxis. The microarray data for both
HUVECs and HCAECs demonstrates an enrichment of genes
associated with both pathways, including diaphanous homolog 3
(DIAPH3), hyaluronan-mediated motility receptor (HMMR), and
anillin (ANLN), an actin binding protein. Furthermore, it is also
important to investigate potential upstream pathways that lead to
the alterations in gene expression seen in the microarray data.
Previously published data have shown that SsnB can suppress the
NF-kB pathway, and prior studies have demonstrated a link
between NF-kB signaling and expression of cell cycle proteins.
Genes for these regulatory proteins, such as CCNE2, CDC6,
CCNB1, and CDC2, contain binding sites for NF-kB. SsnB may
suppress the NF-kB pathway and cause a subsequent downreg-
ulation of the cell cycle regulatory proteins CCNE2 and CDC6.
SsnB has also been shown to inhibit the MAPK pathways,
including JNK, ERK, and p38 signaling, which all affect gene
expression and cell proliferation [23–27]. We need to explore
Figure 4. SsnB inhibits ex vivo angiogenesis in the CAM assay. A. 100 mM SsnB decreased normalized total blood vessel length. B. 100 mM
SsnB decreased normalized branching number. *p,0.05 vs. vehicle control, Newman-Keuls test. C. Representative micrographs demonstrating blood
vessels in the CAM assay (left – vehicle control, right – 100 mM SsnB, circles show approximate position of methylcellulose discs).
doi:10.1371/journal.pone.0070500.g004
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these relationships as potential mechanisms of angiogenesis
inhibition.
Furthermore, the CAM assay allowed us to examine the effects
of SsnB in an ex vivo system involving additional cell types beyond
endothelial cells. Multiple cell types are involved in angiogenesis,
including endothelial cells and supporting cells, such as pericytes,
smooth muscle cells, macrophages, and myofibroblasts. Since our
initial in vitro experiments only involved endothelial cells, we
utilized the CAM assay to address the multicellular nature of
angiogenesis. We are particularly interested in how SsnB affects
macrophages. In the CAM assay, SsnB inhibited blood vessel
branching. It has been demonstrated that macrophage production
of matrix metalloproteinase-9 (MMP-9) plays an important role in
vascular branching during neovascularization [28]. Prior research
has shown that SsnB blocks TLR-2 and TLR-4 mediated
inflammation in human and murine macrophages[3]. Further-
more, TLR signaling activates MMP production in macrophages
[29]. We hypothesize that SsnB blocks TLR signaling and
subsequently inhibits macrophage MMP-9 production required
for blood vessel branching. Additional experiments could examine
this relationship between SsnB, TLR signaling, macrophage
production of MMP-9, and vascular branching.
Our current study with HUVECs and HCAECs demonstrates
that SsnB inhibits angiogenic processes in functional assays,
including the Matrigel tube assay and the Transwell insert cell
migration assay, and that it downregulates multiple genes involved
in pro-angiogenic pathways as shown by microarray analysis. We
have also shown that SsnB inhibits ex vivo angiogenesis in the CAM
assay. Future work with SsnB will reveal more about its
mechanism of action, including cytoskeletal changes and possible
binding sites. Overall, SsnB has proven to be a powerful bioactive
compound with a multitude of useful therapeutic effects, including
anti-angiogenesis and anti-inflammation.
Supporting Information
Figure S1 SsnB inhibits endothelial cell tube formation
on Matrigel. Total tube length as a function of SsnB
concentration in HMVECs, *p,0.05 vs. vehicle control, New-
man-Keuls test.
(TIFF)
Table S1 Gene function enrichment analysis for HU-
VECs in response to SsnB treatment.
(DOCX)
Table S2 Gene function enrichment analysis for
HCAECs in response to SsnB treatment.
(DOC)
Acknowledgments
We thank Dr. Jeremy Barth of the Proteogenomics Facility at the Medical
University of South Carolina for assistance with the microarray analysis.
We would also like to acknowledge Dr. Richard Goodwin and Dr. Jay
Potts from the School of Medicine at the University of South Carolina for
assistance with the CAM assay.
Author Contributions
Conceived and designed the experiments: HB QL DF VR SL. Performed
the experiments: HB VR. Analyzed the data: HB DF VR SL. Contributed
reagents/materials/analysis tools: HB QL DF SL. Wrote the paper: HB
QL DF VR SL.
References
1. Qiu C, Xu X, Zhu H (2008) The studies on the anti-inflammatory and analgesia
effects of SLW. Pharmacology and Clinics of Chinese Materia Medica 14: 7–10.
2. Xiong Y, Deng KZ, Guo YQ, Gao WY, Zhang TJ (2009) New chemical
constituents from the rhizomes of Sparganium stoloniferum. Arch Pharm Res
32: 717–720.
3. Liang Q, Wu Q, Jiang J, Duan J, Wang C, et al. (2011) Characterization of
sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like
receptor antagonist with potent anti-inflammatory properties. J Biol Chem 286:
26470–26479.
4. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med
285: 1182–1186.
5. Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671–674.
6. Staton CA, Reed MW, Brown NJ (2009) A critical analysis of current in vitro
and in vivo angiogenesis assays. Int J Exp Pathol 90: 195–221.
7. Bussolino F, Mantovani A, Persico G (1997) Molecular mechanisms of blood
vessel formation. Trends Biochem Sci 22: 251–256.
8. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653–660.
9. Liekens S, De Clercq E, Neyts J (2001) Angiogenesis: regulators and clinical
applications. Biochem Pharmacol 61: 253–270.
10. Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis–a new target for
future therapy. Vascul Pharmacol 44: 265–274.
11. Wu Z, Cho H, Hampton GM, Theodorescu D (2009) Cdc6 and cyclin E2 are
PTEN-regulated genes associated with human prostate cancer metastasis.
Neoplasia 11: 66–76.
12. Borlado LR, Mendez J (2008) CDC6: from DNA replication to cell cycle
checkpoints and oncogenesis. Carcinogenesis 29: 237–243.
13. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints.
Nat Rev Mol Cell Biol 2: 21–32.
14. Sullivan M, Morgan DO (2007) Finishing mitosis, one step at a time. Nat Rev
Mol Cell Biol 8: 894–903.
15. Tassan JP, Schultz SJ, Bartek J, Nigg EA (1994) Cell cycle analysis of the activity,
subcellular localization, and subunit composition of human CAK (CDK-
activating kinase). J Cell Biol 127: 467–478.
16. O’Farrell PH (2001) Triggering the all-or-nothing switch into mitosis. Trends
Cell Biol 11: 512–519.
17. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999)
The tumour suppressor protein VHL targets hypoxia-inducible factors for
oxygen-dependent proteolysis [see comments]. Nature 399: 271–275.
18. Meng H, Xing G, Sun B, Zhao F, Lei H, et al. (2010) Potent angiogenesis
inhibition by the particulate form of fullerene derivatives. ACS Nano 4: 2773–
2783.
19. Rohde LE, Lee RT (2003) Pathophysiology of atherosclerotic plaque
development and rupture: an overview. Semin Vasc Med 3: 347–354.
20. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, et al. (2012)
Mediterranean diet polyphenols reduce inflammatory angiogenesis through
MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially
protective mechanism in atherosclerotic vascular disease and cancer. Arch
Biochem Biophys 527: 81–89.
21. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, et al. (2006) Emodin inhibits
vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-
2 (KDR/Flk-1) phosphorylation. Int J Cancer 118: 2711–2720.
22. Wang XH, Wu SY, Zhen YS (2004) Inhibitory effects of emodin on
angiogenesis. Yao Xue Xue Bao 39: 254–258.
23. Hsu WH, Lee BH, Pan TM (2010) Red mold dioscorea-induced G2/M arrest
and apoptosis in human oral cancer cells. J Sci Food Agric 90: 2709–2715.
24. Cude K, Wang Y, Choi HJ, Hsuan SL, Zhang H, et al. (2007) Regulation of the
G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell
Biol 177: 253–264.
25. Liu F, Li X, Wang C, Cai X, Du Z, et al. (2009) Downregulation of p21-
activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1.
Int J Cancer 125: 2511–2519.
26. Wang Q, Zou L, Liu W, Hao W, Tashiro S, et al. (2011) Inhibiting NF-kappaB
activation and ROS production are involved in the mechanism of silibinin’s
protection against D-galactose-induced senescence. Pharmacol Biochem Behav
98: 140–149.
27. Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S (2008) NF-KappaB
expression correlates with apoptosis and angiogenesis in clear cell renal cell
carcinoma tissues. J Exp Clin Cancer Res 27: 53.
28. Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS (2004) Matrix
metalloproteinase-9 is required for adequate angiogenic revascularization of
ischemic tissues: potential role in capillary branching. Circ Res 94: 262–268.
29. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H (2008) TLR signaling by
tumor and immune cells: a double-edged sword. Oncogene 27: 218–224.
Sparstolonin B Inhibits Pro-Angiogenic Functions
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e70500
